The Expression Of CCL20in CIA And The Therapeutic Effect Of Anti-CCL20Therapy On CIA

Objective To investgate the expression of chemotactic factor CCL20in murine collagen-induced arthritis(CIA) and the therapeutic effect of anti-CCL20therapy on CIA, and to explore its potential value in the treatment of rheumatoid arthritis(RA).Methods①The model of CIA was established, forty DBA/1murines were randomly divided into four groups:healthy control group, CIA model group, CCL20monoclonal antibody group, tripterygium wilfordii group.②Joint swelling degree of murines on different time points was observed.③The pathological changes were evaluated, and the serum tumor necrosis factor-α(TNF-α) and interleukin-1β(IL-1β) level were also measured.④The pathological changes in four groups were analyzed by the statistical SPSS17.0.Result①Comparing to that of control group(2.83±1.37ng/L), the serum CCL20level in CIA model group(29.45±4.92ng/L) was increased significantly (P<0.05).②the serum CCL20level in CIA model group correlates with TNF-a and IL-1β;③Compared with CIA model group, both CCL20monoclonal antibody group and tripterygium wilfordii group got improvement in general condition, joint swelling, inflammation cell infiltration synoviocyte proliferation, synoviocyte apoptosis, serum level of TNF-a and IL-1β (P<0.05),the serum level of TNF-a and IL-1β in CIA model group were (63.1±2.82) ng/L,(83.72±4.04)ng/L respectively, tripterygium wilfordii group:(43.15±2.31) ng/L,(53.78±5.89) ng/L, CCL20monoclonal antibody group:(40.91±2.02) ng/L,(56.77±4.98)ng/L, The two treatment groups compared with the model group, the difference was statistically significant (P<0.05),④In the pathological changes,there were no significant difference between CCL20monoclonal antibody group and tripterygium wilfordii group(P>0.05).Conclusions:CCL20is up-regulated expressioned in CIA murine,and it correlated with TNF-a and IL-1β; blocking the expressions by CCL20monoclonal antibody can effectively relieve the joint inflammation, and its effect of treatment is similar to tripterygium wilfordii. CCL20monoclonal antibody has potential value in treatment of RA.